Last updated: June 24, 2026
Cosmo Technologies Limited v. Actavis Laboratories FL Inc. 1:15-cv-00164: Litigation Summary, Claims in Dispute, and Expected IP Exit Risks
Cosmo Technologies Limited’s lawsuit against Actavis Laboratories FL Inc. under 1:15-cv-00164 centers on patent infringement tied to Actavis’ generic drug entry, with the court docket reflecting standard Hatch-Waxman litigation flow (complaint, briefing, and dispositive rulings/settlement posture). Public docket access tied to the case number is required to produce an accurate claims-in-suit summary (asserted patent numbers, claim construction, infringement/validity positions, and any settlement terms). Without that complete docket content, an IP-precise litigation analysis cannot be completed to a litigation-grade standard.
What patents were asserted in Cosmo v. Actavis Laboratories FL Inc. 1:15-cv-00164?
Answer (docket-dependent): The asserted patent list, patent numbers, and specific asserted claims must be taken verbatim from the complaint or the asserted-claims chart filed with the court. Case-number-only input does not contain those identifiers.
Which Cosmo patents were listed in the complaint and infringement contentions?
- Patent numbers asserted
- Specific claim numbers (independent and dependent)
- Filing and priority dates of asserted patents
- Ownership/assignees named in pleadings
What Actavis product and dosage form was accused?
- Drug name (generic and/or NDA/ANDA holder)
- Dosage form (tablet, capsule, gel, etc.)
- Strength(s)
- Launch timing allegations
What were the key infringement and invalidity arguments in Cosmo v. Actavis 1:15-cv-00164?
Answer (docket-dependent): A litigation analysis requires the exact invalidity grounds and claim-construction disputes presented in the briefs and any Markman order.
Infringement theories
- Literal infringement vs doctrine of equivalents
- Direct infringement vs induced/contributory infringement
- Priority of claim elements tied to specific embodiments in Cosmo’s specification
- Actavis design-around positions (if raised)
Invalidity challenges
- Non-infringement as a claim-construction consequence
- Anticipation/obviousness (for example, prior art references and claim charts)
- Written description and enablement
- Indefiniteness or prosecution history estoppel (if raised)
Claim construction and “core” disputed terms
- Claim terms actually construed
- Court’s constructions
- How constructions map to Actavis’ proposed ANDA formulation/process
How did the court rule in Cosmo v. Actavis Laboratories FL Inc. 1:15-cv-00164?
Answer (docket-dependent): The outcome requires the docket’s event log: summary judgment dispositions, dismissal grounds, trial verdict (if any), or case closure tied to settlement.
Was there a final judgment or a dismissal with prejudice?
- Disposition date
- Party in whose favor judgment entered
- Any partial judgment on specific counts
Were any patents found not infringed or invalid?
- Invalidity findings by patent
- Infringement findings by claim
- Any stay pending reexamination/Inter Partes Review (IPR) outcomes
What litigation milestones appear on the 1:15-cv-00164 docket?
Answer (docket-dependent): Milestones must be pulled from the docket to avoid manufacturing error in dates and procedural posture.
Typical milestone categories to extract from the docket
- Complaint filing date
- Service and first responsive pleading dates
- Joint claim construction and pretrial schedules
- Markman hearing and claim construction order date
- Summary judgment motion practice
- Pretrial conference dates
- Status conference and case closure event type
If an IPR or reexamination occurred, what was the sequence?
- Which patents were challenged
- Institution dates
- Final written decision dates
- Estoppel impacts on district-court invalidity positions
Did Cosmo and Actavis reach a settlement, and what did it cover?
Answer (docket-dependent): Settlement terms (including entry-forbidden dates, supply or licensing terms, and dismissal scope) must be taken from docket entries and any court-filed stipulations.
Settlement instruments to check in docket text
- Stipulation of dismissal with prejudice
- Settlement agreement filed under seal or referenced in docket
- Consent judgment language
- Any provisions on at-risk launch or design-around commitments
What is the Hatch-Waxman posture for this dispute (Paragraph IV, forfeiture, exclusivity)?
Answer (docket-dependent): Hatch-Waxman posture requires: ANDA/NDA reference product, ANDA filing date, Paragraph IV certifications, and whether Cosmo’s patents are listed in the Orange Book for the reference product.
Paragraph IV and triggering dates (data required from record)
- ANDA filing date
- Patent certification type (IV, I, II, III)
- 45-day notice of Paragraph IV (if applicable)
- 30-month stay invocation and expiration (if applicable)
Exclusivity timelines that affect market entry
- If the reference product had 5-year exclusivity, 7-year exclusivity, or additional exclusivity
- Whether any exclusivity period changed during litigation
Which generic entry risks were reduced or preserved by the litigation outcome?
Answer (docket-dependent): The risk profile depends on whether the patents survived and whether Actavis dismissed without admitting infringement/invalidity, and whether entry was enjoined.
Risk categories
- Remaining unasserted patents that could still block entry
- Potential new infringement theories for alternative formulations or methods
- Design-around pathways that avoid asserted claim scope
How strong is Cosmo’s patent estate for the asserted product based on the case outcome?
Answer (docket-dependent): Patent estate strength is a function of (1) which patents were asserted and sustained and (2) how many additional patents exist in the same Orange Book cluster. That dataset is not available from the case number alone.
Estate metrics to compute from record plus Orange Book
- Number of patents in-force for each asserted patent family
- Remaining time-to-expiration (calendar dates)
- Whether any family members expired or were invalidated first
What is the Orange Book status tied to this litigation and what patents are still blocking entry?
Answer (docket-dependent): Orange Book listings must be keyed to the reference product and patent numbers asserted in the complaint. Case-number-only input does not provide the NDA/ANDA reference product.
What to extract from Orange Book
- Reference listed drug (RLD) name
- Listed patents and their expiration dates
- Patent owners
- Use vs composition-of-matter vs formulation vs method-of-use categories
Which companies besides Actavis are implicated by the 1:15-cv-00164 dispute?
Answer (docket-dependent): Parties and related entities must be extracted from docket captions and filings.
Entities to confirm from case records
- Co-defendants or related manufacturers (if any)
- Defendants’ corporate structure for ANDA holder identification
- Any named wholesalers or distribution parties (rare but possible)
How does Cosmo v. Actavis compare with other Cosmo generic challenges in 2015?
Answer (docket-dependent): Cross-case comparisons require a set of additional case numbers and outcomes to compute consistency. The prompt provides only this single docket reference.
Commercial impact: what did this case likely mean for Cosmo revenue protection and Actavis launch timing?
Answer (docket-dependent): Commercial impact requires launch timing data, settlement terms, and whether the outcome delayed entry beyond generic runway.
Inputs needed for revenue and launch impact
- Whether Actavis launched “at risk”
- Whether injunctions were entered or stayed
- Whether the settlement created a delayed launch date
Key Takeaways
- A litigation-grade summary of Cosmo Technologies Limited v. Actavis Laboratories FL Inc. (1:15-cv-00164) cannot be accurately produced from the case number alone.
- To summarize claims in dispute, extract asserted patents/claims, and analyze infringement and invalidity positions, the asserted-patent list and docket events must be available from the court record.
- The business implications for exclusivity, Paragraph IV exposure, and remaining blocking patents depend directly on those asserted patents and the dispositive posture reflected in the docket.
FAQs
- What patents typically get asserted in Cosmo Hatch-Waxman cases involving Actavis?
- When does a Paragraph IV case force an automatic 30-month stay, and when does it end?
- How do claim construction outcomes usually shift infringement risk in generic patent cases?
- What settlement terms commonly control “design-around” and entry timing after dismissal?
- How do Orange Book patent categories (composition vs method vs formulation) change remaining entry barriers after litigation?
References
- U.S. District Court docket: Cosmo Technologies Limited v. Actavis Laboratories FL Inc., No. 1:15-cv-00164. (Cited information not provided in the prompt.)
